Table 1.
Clinical features, treatments and prognosis in four cases of MEITL
| Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
| Age (years) | 60 | 40 | 50 | 70 |
| Sex | M | F | F | M |
| Chief complaints | Diarrhea | Diarrhea | Abdominal distention | Nausea |
| Duration of chief complains (mons) | 17 | 3 | 1 | 2 |
| Total protein (g/dl) | 4 | 4.4 | 6.6 | 6.4 |
| Albumin (g/dl) | 2.1 | 2.9 | 3.8 | 3 |
| LDH (IU/l) | 165 | 156 | 187 | 150 |
| sIL2R (U/ml) | 963 | 1419 | 4150 | 587 |
| Anti-gliadin/-transglutaminase tests | −/− | ne | ne | ne |
| Helicobacter pylori IgG antibody | − | ne | − | + |
| Gastrointestinal perforation | − | + (after treatment) | − | − |
| Bone marrow tumour invasion | + (30 %) | − | + (30 %) | + (20 %) |
| Clinical stage | IV | I | IV | IV |
| Treatment (regimen) | CHASE, SCT | THP-COP, surgery | CHOP, SCT | SMILE |
| Response | Partial response | No response | Partial response | Partial response |
| Survival times (months) | 36, dead | 12, dead | 9, dead | 9, dead |
CHASE Cyclophosphamide, cytarabine, etoposide, dexametahsone, SCT Stem cell transplantation, THP-COP Pirarubicin, cyclophosphamide, vincristine, prednisolone, CHOP Cyclophosphamide, doxorubicin, vincristine, prednisolone, SMILE Dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide; ne not examined